Dana Farber Cancer Institute ( Site 0012) — Boston, Massachusetts

Dana Farber Cancer Institute ( Site 0012) is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute ( Site 0012) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Prostate Cancer, Prostatic Neoplasms.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute ( Site 0012)?

Dana Farber Cancer Institute ( Site 0012) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute ( Site 0012) conducted?

Dana Farber Cancer Institute ( Site 0012) has 1 clinical trials on record, with 1 currently active. Their work covers Prostate Cancer, Prostatic Neoplasms.

Is Dana Farber Cancer Institute ( Site 0012) accredited by Crixeo Health?

Dana Farber Cancer Institute ( Site 0012) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute ( Site 0012)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.